BRPI0810211A2 - Citolisina dependente de colesterol mutante purficada, composição, vacina, método para vacinar um paciente, anticorpo monoclonal, ácido nucléico, e, célula hospedeira. - Google Patents

Citolisina dependente de colesterol mutante purficada, composição, vacina, método para vacinar um paciente, anticorpo monoclonal, ácido nucléico, e, célula hospedeira.

Info

Publication number: BRPI0810211A2
Authority: BR; Brazil
Prior art keywords: dependent; cytolisin; vaccinating; vaccine; patient
Prior art date: 2007-04-13

Application number

BRPI0810211-2A2A

Other languages

English (en)

Inventor

Rodney K Tweten

Original Assignee

Univ Oklahoma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-04-13

Filing date

2008-04-14

Publication date

2014-10-21

2008-04-14 Application filed by Univ Oklahoma filed Critical Univ Oklahoma

2014-10-21 Publication of BRPI0810211A2 publication Critical patent/BRPI0810211A2/pt

Links

HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title 2
230000001419 dependent effect Effects 0.000 title 2
235000012000 cholesterol Nutrition 0.000 title 1
150000007523 nucleic acids Chemical class 0.000 title 1
102000039446 nucleic acids Human genes 0.000 title 1
108020004707 nucleic acids Proteins 0.000 title 1
229960005486 vaccine Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

BRPI0810211-2A2A 2007-04-13 2008-04-14 Citolisina dependente de colesterol mutante purficada, composição, vacina, método para vacinar um paciente, anticorpo monoclonal, ácido nucléico, e, célula hospedeira. BRPI0810211A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US92328107P	2007-04-13	2007-04-13
PCT/US2008/060250 WO2009023300A2 (en)	2007-04-13	2008-04-14	Mutants of cholesterol-dependent cytolysins and uses thereof

Publications (1)

Publication Number	Publication Date
BRPI0810211A2 true BRPI0810211A2 (pt)	2014-10-21

Family

ID=40351376

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0810211-2A2A BRPI0810211A2 (pt)	2007-04-13	2008-04-14	Citolisina dependente de colesterol mutante purficada, composição, vacina, método para vacinar um paciente, anticorpo monoclonal, ácido nucléico, e, célula hospedeira.

Country Status (6)

Country	Link
US (2)	US8128939B2 (pt)
EP (2)	EP2386567B1 (pt)
AU (1)	AU2008287286B2 (pt)
BR (1)	BRPI0810211A2 (pt)
CA (1)	CA2683748C (pt)
WO (1)	WO2009023300A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2008287286B2 (en)	2007-04-13	2013-10-10	The Board Of Regents Of The University Of Oklahoma	Mutants of cholesterol-dependent cytolysins and uses thereof
CN106008679A (zh)	2008-12-24	2016-10-12	荷兰王国卫生福利和运动部国家公共卫生和环境研究所	修饰的肺炎链球菌溶血素(ply)多肽
AU2011336366B2 (en)	2010-12-03	2016-05-12	Sanofi Pasteur Limited	Composition for immunization against Streptococcus pneumoniae
JPWO2012121395A1 (ja) *	2011-03-09	2014-07-17	国立大学法人徳島大学	コレステロール依存性細胞溶解毒素の変異体及びそのｄｄｓへの利用
US9181308B2 (en) *	2011-03-28	2015-11-10	St. Jude Children's Research Hospital	Methods and compositions employing immunogenic fusion proteins
EP2694667B1 (en)	2011-04-08	2016-12-07	Baystate Medical Center, Inc.	Methods, compositions and kits for assaying mitochondrial function
RU2632651C2 (ru)	2011-05-11	2017-10-06	Чилдрен'С Медикал Сентер Корпорейшн	Модифицированный биотин-связывающий белок, слитые белки на его основе и их применение
US9765125B2 (en)	2012-01-20	2017-09-19	Genocea Biosciences, Inc.	Fused antigen vaccines and compositions against Streptococcus pneumoniae
EP4272750A3 (en)	2013-02-07	2024-01-24	Children's Medical Center, Corp.	Protein antigens that provide protection against pneumococcal colonization and/or disease
CA2903716C (en)	2013-03-08	2019-04-09	Pfizer Inc.	Immunogenic fusion polypeptides
US11207396B2 (en)	2013-05-17	2021-12-28	The Board Of Regents Of The University Of Texas System	Immunization to protect against adverse cardiac events relating to pneumococcal infection
ES2993430T3 (en) *	2014-11-21	2024-12-30	Univ Oklahoma	Pneumolysin mutants and methods of use thereof
CN118272512A (zh) *	2016-04-06	2024-07-02	牛津纳米孔科技公开有限公司	突变体孔
EP3600400A4 (en)	2017-03-28	2021-01-13	The Children's Medical Center Corporation	MULTIPLE ANTIGEN (MAPS) BASED STAPHYLOCOCCUS AUREUS VACCINE, IMMUNOGENIC COMPOSITION AND USES THEREOF
SG11201912601RA (en)	2017-06-23	2020-01-30	Nosocomial Vaccine Corp	Immunogenic compositions
HUE068482T2 (hu)	2017-09-07	2025-01-28	Merck Sharp & Dohme Llc	Pneumococcus-poliszacharidok és azok felhasználása immunogén poliszacharid-hordozóprotein konjugátumokban
CN112969474A (zh)	2018-09-12	2021-06-15	艾芬尼维克斯公司	多价肺炎球菌疫苗
CN113164580B (zh)	2018-09-12	2025-06-10	儿童医疗中心公司	肺炎球菌融合蛋白疫苗
MX2024002779A (es)	2021-09-09	2024-06-11	Affinivax Inc	Vacunas neumocócicas multivalentes.
EP4433080A1 (en)	2021-11-18	2024-09-25	Matrivax, Inc.	Immunogenic fusion protein compositions and methods of use thereof
CN115820677B (zh) *	2022-11-04	2026-06-05	广州达安基因股份有限公司	重组slo抗原的制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4686102A (en)	1984-04-12	1987-08-11	American Cyanamid Company	Multivalent pneumococcal vaccine and preparation thereof
JP3237842B2 (ja) *	1988-12-16	2001-12-10	オランダ国	ニューモリシンミュータント及びそれから製造されたニューモコッカルワクチン
US6716432B1 (en)	1988-12-16	2004-04-06	James Cleland Paton	Pneumolysin mutants and pneumococcal vaccines made therefrom
US5854416A (en)	1991-11-14	1998-12-29	The United States Of America As Represented By The Department Of Health And Human Services	Streptococcus pneumoniae 37-KDA surface adhesin a protein and nucleic acids coding therefor
US5565204A (en)	1994-08-24	1996-10-15	American Cyanamid Company	Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
AU723116B2 (en)	1995-06-07	2000-08-17	Regents Of The University Of Minnesota	Mutants of streptococcal toxin A and methods of use
AU740956B2 (en)	1997-07-21	2001-11-15	Baxter Healthcare Sa	Modified immunogenic pneumolysin compositions as vaccines
US6224880B1 (en)	1997-09-24	2001-05-01	Merck & Co., Inc.	Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US6903184B1 (en)	1998-03-02	2005-06-07	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Multiple antigenic peptides immunogenic against Streptococcus pneumonia
WO2000005378A2 (en)	1998-07-22	2000-02-03	Id-Lelystad Instituut Voor Dierhouderij En Diergezondheid B.V.	Streptococcus suis vaccines and diagnostic tests
CA2355364C (en)	1998-12-21	2014-03-18	Medimmune, Inc.	Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
US6887480B1 (en)	1999-06-10	2005-05-03	Medimmune, Inc.	Streptococcus pneumoniae proteins and vaccines
KR100415192B1 (ko)	2001-04-18	2004-01-16	삼성전자주식회사	반도체 메모리 장치에서 읽기와 쓰기 방법 및 장치
US7262024B2 (en)	2001-12-20	2007-08-28	Id Biomedical Corporation	Streptococcus antigens
CN100443116C (zh)	2002-11-07	2008-12-17	新纳几美国公司	治疗或预防肺炎球菌感染的组合物及其用途
WO2005076696A2 (en) *	2004-02-13	2005-08-25	Sanofi Pasteur Limited	Pneumolysin derivatives
GB0410220D0 (en)	2004-05-07	2004-06-09	Kirkham Lea Ann	Mutant pneumolysin proteins
SI22410A (sl)	2006-11-13	2008-06-30	Kolektor Liv Predelava Plastike, D.D.O.	Spojnica cevi sesalnika za prah
AU2008287286B2 (en)	2007-04-13	2013-10-10	The Board Of Regents Of The University Of Oklahoma	Mutants of cholesterol-dependent cytolysins and uses thereof

2008
- 2008-04-14 AU AU2008287286A patent/AU2008287286B2/en active Active
- 2008-04-14 US US12/102,696 patent/US8128939B2/en active Active
- 2008-04-14 WO PCT/US2008/060250 patent/WO2009023300A2/en not_active Ceased
- 2008-04-14 BR BRPI0810211-2A2A patent/BRPI0810211A2/pt not_active IP Right Cessation
- 2008-04-14 CA CA2683748A patent/CA2683748C/en active Active
- 2008-04-14 EP EP11174235.9A patent/EP2386567B1/en active Active
- 2008-04-14 EP EP08827230A patent/EP2147015A4/en not_active Withdrawn
2012
- 2012-02-21 US US13/401,460 patent/US9228001B2/en active Active

Also Published As

Publication number	Publication date
AU2008287286B2 (en)	2013-10-10
US20120148624A1 (en)	2012-06-14
CA2683748C (en)	2016-02-16
EP2386567A2 (en)	2011-11-16
EP2386567A3 (en)	2012-02-15
WO2009023300A3 (en)	2009-06-25
CA2683748A1 (en)	2009-02-19
AU2008287286A1 (en)	2009-02-19
WO2009023300A2 (en)	2009-02-19
EP2147015A4 (en)	2011-01-26
EP2147015A2 (en)	2010-01-27
EP2386567B1 (en)	2014-10-29
US9228001B2 (en)	2016-01-05
US20090285846A1 (en)	2009-11-19
US8128939B2 (en)	2012-03-06

Similar Documents

Publication	Publication Date	Title
BR112012022046A2 (pt)	2017-02-14	''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''.
BRPI1008145A2 (pt)	2016-03-15	proteína de ligação de antígeno biespecífico, método para preparação de uma proteína de ligação de antígeno biespecífico, célula hospedeira, composição farmacêutica, uso da proteína de ligação de antígeno biespecífico e método para o tratamento de um paciente.
BRPI0922106A2 (pt)	2018-10-16	anticorpo monoclonal isolado, molécula de ácido nucleico isolada, célula hospedeira, método para produzir um anticorpo monoclonal isolado, composição farmacêutica, e, uso da composição
BRPI0813242A2 (pt)	2015-08-18	Proteína de ligação a antígeno isolada, ácido nucléico isolado, vetor, célula hospedeira isolada, método para a produção de uma proteína de ligação a antígeno, e, composição.
BRPI0919377A2 (pt)	2016-09-27	anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
BR112014000341A2 (pt)	2017-02-14	proteína de ligação ao antígeno, método para tratamento de um paciente com uma doença, uso de uma proteína de ligação ao antígeno, ácido nucleico, e, célula hospedeira
BRPI0814939A2 (pt)	2015-01-27	Entidade química, composição farmacêutica, e, método para tratar uma infecção viral em um mamífero.
BR112012020372A8 (pt)	2018-01-02	anticorpo que se liga ao csf-1r humano, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira e método para a produção de um anticorpo recombinante
BRPI0916964A2 (pt)	2015-11-24	polipetídeo, anticorpo, ácido nucléico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição e uso do polipeptídeo
BRPI0814781A2 (pt)	2014-10-21	Proteína, sequência de ácido nucleico, método para a produção de ácido itacônico, vetor, célula hospedeira, e, uso de um ácido cis-aconítico
IL206108A (en)	2013-07-31	Antibody @ Bi-value @ Bi-specific L @ method for its preparation, compounds containing it @ and cell @ surrogate
BR112012004221A2 (pt)	2016-11-29	"anticorpos, composição farmacêutica, uso do anticorpo, ácido nucleico, vetores de expressão, célula hospedeira procariótica e método para a produção de um anticorpo humanizado recombinante"
BRPI0815494A2 (pt)	2015-07-14	Método implementado por computador, e, sistema.
BRPI0822099A2 (pt)	2017-05-23	membro de ligação isolado, uso de um membro de ligação isolado, método parav tratar um distúrbio, molécula de ácido nucléico isolada, célula hospedeira, e, método para produzir um membro de ligação
BRPI0807295A2 (pt)	2014-05-06	Método para planejar um procedimento com agulha, sistema para planejar um procedimento com agulha e meio legível em computador.
BR112012024287A2 (pt)	2017-03-01	anticorpo, composição farmacêutica, método, ácido nucleico, vetor de expressão e célula hospedeira
BRPI0814459A2 (pt)	2014-10-21	Célula de inseto, método para produzir um vírion parvoviral recombinante em uma célula de inserto, e, construção de ácido nucleico.
BRPI0823030A2 (pt)	2015-07-28	Sistema de elevador, e, método para fazer um sistema de elevador.
BRPI0810356A2 (pt)	2014-10-21	Sistema de aquecimento para uma formação de subsuperfície, e, método para aquecer uma formação de subsuperfície.
BRPI1008441A2 (pt)	2016-10-11	anticorpo humanizado, composição farmacêutica, método para tratar e prevenir um distúrbio de célula b em sujeito, composição de anticorpo anti-cd-20 humanizado, ácido nucléico isolado e célula hospedeira.
BR112012014414A2 (pt)	2017-04-04	"método, sistema e meio legível por máquina codificado com instruções, para adaptar um fluxo de trabalho médico"
BRPI0814582A2 (pt)	2015-01-20	Dispositivo, método, e, usos de um método, e da quantidade de ácidos nucleicos virais totais.
NL2003118A1 (nl)	2010-01-18	Alignment system, lithographic system and method.
BR112012002603A2 (pt)	2016-11-22	composição imunogênica, proteína de fusão, polinucleotídeo, vacina, processo para preparar a vacina, uso da composição imunogênica, e, método para tratar ou prevenir doença estafilocócica.
BR112014000263A2 (pt)	2017-02-14	anticorpo isolado ou fragmento de ligação de antígeno do mesmo, molécula de ácido nucleico, e, composição farmacêutica

Legal Events

Date	Code	Title	Description
2015-10-13	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2016-09-13	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 8A ANUIDADE.
2017-01-10	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.
2022-07-12	B350	Update of information on the portal [chapter 15.35 patent gazette]